SOPH Chief Medical Officer Menu Philippe Sells $36K of Stock
Chief Medical Officer Menu Philippe sold shares valued at $36,303 on October 12, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Menu Philippe, Chief Medical Officer at SOPHiA GENETICS SA ($SOPH), sold 5,000 shares at an average price of $7.26, worth about $36,303, on October 12, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $SOPH is down 6.8% to date (from the $7.22 close on Oct 12, 2026).
SOPH
SOPHiA GENETICS SA
Key Points
- Menu Philippe, Chief Medical Officer at SOPHiA GENETICS, sold 5,000 shares at a price of $7.26 each, totaling $36,303 on October 12, 2026.
- The stock recently traded around $6.81, about 14.3% below its 50-day moving average of $7.95.
- SOPHiA GENETICS has a market cap of approximately $564.6 million and reports a revenue growth of 27.2% year-over-year.
Get $SOPH trade alerts by text
We text you when insiders, Congress or big funds trade $SOPH. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated SOPHiA GENETICS SA alert may contain errors. Disclosures
Chief Medical Officer Menu Philippe sold 5,000 shares of SOPHiA GENETICS SA (SOPH) for about $36,303 on October 12, 2026. This planned sale occurred at an average price of $7.26 per share.
Inside Menu Philippe's Trade
Philippe's sale of 5,000 shares represents a planned transaction, reflecting the insider's decision to liquidate part of his holdings. This sale adds to a series of insider transactions at the company, following earlier sales by other executives.
Other Institutional Activity in SOPHiA GENETICS
Generation Investment Management LLP holds 6,789,560 shares of SOPHiA GENETICS, valued at approximately $45.7 million. AIGH Capital Management LLC increased its stake by 1,977,097 shares, bringing its total to 3,954,194 shares worth about $26.6 million. Royce & Associates LP added 1,565,454 shares, now holding 3,381,736 shares valued at around $22.8 million. Principal Financial Group, Inc. also raised its holdings by 955,031 shares, ending with 2,364,256 shares worth about $15.9 million.
SOPHiA GENETICS SA Stock Down 6.6%
As of October 16, 2026, SOPHiA GENETICS trades below its 50-day moving average of $7.95 and is 14.3% lower than that average. The stock is also 24.2% below its 52-week high of $8.98 but remains 81.6% above its 52-week low of $3.75. The stock's recent price of $6.81 is approximately 30.2% below the mean price target of $9.75 set by analysts.
Recent Earnings
SOPHiA GENETICS reported trailing twelve-month revenue of $86.2 million, reflecting a year-over-year growth of 27.2%. However, the company reported a net margin of -93.9% and a return on equity of -101.2%. The next earnings report is scheduled for November 3, 2026.
Insider Buying and Selling at SOPHiA GENETICS SA
In addition to Philippe's sale, CEO Jurgi Camblong sold 1,373 shares at $5.70 on June 25, 2026, valued at $7,826.10. Camblong also sold 31,940 shares at $3.16 on June 26, 2026. Chief Technology Officer Abhimanyu Verma sold 6,944 shares at $5.51 on June 25, 2026, totaling $38,261.44. These transactions reflect ongoing insider selling activity at SOPHiA GENETICS.
Analysts Set New Price Targets
On October 12, 2026, HC Wainwright & Co. reiterated a Buy rating for SOPHiA GENETICS with a price target of $14.0. Earlier, on August 5, they had maintained a Buy rating, raising the target from $12.0 to $14.0. BTIG also maintained a Buy rating with a target of $9.0.
About SOPHiA GENETICS
SOPHiA GENETICS SA is a healthcare technology company based in Rolle, Switzerland. It specializes in cloud-based software solutions for analyzing medical data and providing insights from various diagnostic sources. This insider trade comes amid a backdrop of fluctuating stock performance and ongoing corporate developments.
Bottom Line
Investors should keep an eye on upcoming earnings on November 3, 2026, along with any further insider transactions that may impact market perception. Menu Philippe’s planned sale adds to the narrative of insider activity at SOPHiA GENETICS, a company navigating a competitive healthcare technology landscape.
Related Filing Alerts
Source: Menu Philippe's Form 4 filing on $SOPH (Oct 12, 2026). Find the original filing: SOPH Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts